742107-57-9

Usage

Uses

Used in Pharmaceutical Industry:
C-(3,4-DICHLORO-PHENYL)-C-PHENYL-METHYLAMINE HYDROCHLORIDE is used as an intermediate in the synthesis of various pharmaceutical drugs for its potential biological activity and ability to contribute to the development of new chemical entities.
Used in Research Applications:
C-(3,4-DICHLORO-PHENYL)-C-PHENYL-METHYLAMINE HYDROCHLORIDE is used as a research compound to study its properties and potential applications in the field of chemistry and drug discovery, aiding scientists and researchers in their quest to create novel organic compounds and therapeutic agents.

Upstream product

• 742107-55-7 (RS)-C-(3,4-dichloro-phenyl)-C-phenyl-methylamine 
• 134917-58-1 (3,4-dichlorophenyl)phenylmethanone oxime 

Relevant academic research and scientific papers

MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS

The present invention relates to a compound of formula (I), aN-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein R1 represents hydrogen, C1-6alkyl, C3-7

MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS

The present invention relates to a compound of formula (I),a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein R1 is hydrogen, C1-6alkyl, C3-7cycloalkyl, aryl or heteroaryl; R2 is halo, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, cyano, aminocarbonyl, amino, mono-or di(C1-4alkyl)amino, nitro, aryl or aryloxy; R3 is hydrogen, cyano, C1-6alkyl optionally substituted with hydroxy, C(=O)-O-R5, C(=O)-NR6aR6b, S(=O)2-NR6aR6b, C(=O)-R7; R4 is hydrogen, cyano, C1-6alkyl optionally substituted with hydroxy, C(=O)-O-R5, C(=O)-NR6aR6b, S(=O)2-NR6aR6b, C(=O)-R7; n is 1, 2, 3, 4 or 5;provided that at least one of R3 or R4 is other than hydrogen; and that if R3 represents C(=O)-OH, C(=O)-O-C1-6alkyl or C(=O)-O-C2-6alkenyl, then R4 is other than hydrogen; and that if R3 represents CH2OH and R1 represents hydrogen, then R4 is other than hydrogen; and that if R3 represents C(=O)-NH-C1-4alkyl-NH2 and R1 represents hydrogen, then R4 is other than hydrogen; and that if R3 represents formula (II) and R1 represents hydrogen, then R4 is other than hydrogen; having CCR2 receptor antagonistic properties. The invention also relates to processes for preparing the compounds of formula (I) and pharmaceutical compositions comprising them.